110 related articles for article (PubMed ID: 20027336)
1. Molecular markers of tumors.
Kushlinsky NE; Gershtein ES; Ovchinnikova LK; Digaeva MA
Bull Exp Biol Med; 2009 Aug; 148(2):230-7. PubMed ID: 20027336
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis.
Chevalier S; Defoy I; Lacoste J; Hamel L; Guy L; Bégin LR; Aprikian AG
Mol Cell Endocrinol; 2002 Mar; 189(1-2):169-79. PubMed ID: 12039075
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis in epithelian ovarian cancer.
Bamberger ES; Perrett CW
Mol Pathol; 2002 Dec; 55(6):348-59. PubMed ID: 12456770
[TBL] [Abstract][Full Text] [Related]
4. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
Candido Dos Reis F; Moreira de Andrade J; Bighetti S
Gynecol Obstet Invest; 2002; 54(3):132-6. PubMed ID: 12571433
[TBL] [Abstract][Full Text] [Related]
5. Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways.
Wei K; Kuhnert F; Kuo CJ
J Mol Med (Berl); 2008 Feb; 86(2):161-9. PubMed ID: 17891365
[TBL] [Abstract][Full Text] [Related]
6. VEGFs, angiopoietins, Ephrins and their receptors: putative targets for tumor therapy?
Marmé D
Ann Hematol; 2002; 81 Suppl 2():S66. PubMed ID: 12611080
[No Abstract] [Full Text] [Related]
7. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.
Färkkilä A; Anttonen M; Pociuviene J; Leminen A; Butzow R; Heikinheimo M; Unkila-Kallio L
Eur J Endocrinol; 2011 Jan; 164(1):115-22. PubMed ID: 21041381
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.
Gaffney DK; Haslam D; Tsodikov A; Hammond E; Seaman J; Holden J; Lee RJ; Zempolich K; Dodson M
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):922-8. PubMed ID: 12829126
[TBL] [Abstract][Full Text] [Related]
9. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
10. Tumor endothelial markers as a target in cancer.
Ribatti D; Ranieri G; Basile A; Azzariti A; Paradiso A; Vacca A
Expert Opin Ther Targets; 2012 Dec; 16(12):1215-25. PubMed ID: 22978444
[TBL] [Abstract][Full Text] [Related]
11. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
von Marschall Z; Scholz A; Cramer T; Schäfer G; Schirner M; Oberg K; Wiedenmann B; Höcker M; Rosewicz S
J Natl Cancer Inst; 2003 Mar; 95(6):437-48. PubMed ID: 12644537
[TBL] [Abstract][Full Text] [Related]
12. [VEGF in neoplastic angiogenesis].
Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
Vestn Ross Akad Med Nauk; 2012; (2):23-33. PubMed ID: 22642175
[TBL] [Abstract][Full Text] [Related]
13. From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy.
Stacker SA; Achen MG
Lymphat Res Biol; 2008; 6(3-4):165-72. PubMed ID: 19093789
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival.
Donnem T; Andersen S; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
Cancer; 2010 Dec; 116(24):5676-85. PubMed ID: 20737536
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
16. Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the Notch signaling.
Dong Y; Zhang T; Li J; Deng H; Song Y; Zhai D; Peng Y; Lu X; Liu M; Zhao Y; Yi Z
PLoS One; 2014; 9(12):e113830. PubMed ID: 25485753
[TBL] [Abstract][Full Text] [Related]
17. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.
Harrington LS; Sainson RC; Williams CK; Taylor JM; Shi W; Li JL; Harris AL
Microvasc Res; 2008 Mar; 75(2):144-54. PubMed ID: 17692341
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenesis in cancer therapy.
Ichihara E; Kiura K; Tanimoto M
Acta Med Okayama; 2011 Dec; 65(6):353-62. PubMed ID: 22189475
[TBL] [Abstract][Full Text] [Related]
19. [Production and reception of growth factors in the placenta during physiological and gestosis complicated pregnancy].
Krukier II; Pogorelova TN; Orlov VI
Biomed Khim; 2007; 53(1):86-90. PubMed ID: 17436688
[TBL] [Abstract][Full Text] [Related]
20. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Brower V
J Natl Cancer Inst; 2009 Jun; 101(12):846-7. PubMed ID: 19509354
[No Abstract] [Full Text] [Related]
[Next] [New Search]
